Simvastatin attenuates hypertrophic responses induced by cardiotrophin-1 via JAK-STAT pathway in cultured cardiomyocytes

Molecular and Cellular Biochemistry
LiJun WuBing Lang

Abstract

Cardiotrophin-1 (CT-1) is a cytokine involved in the growth and survival of cardiac cells via activation of the Janus activated kinase/signal transducer activator of transcription (JAK/STAT). Statins, 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, have effects that extend beyond cholesterol reduction and inhibit vascular smooth muscle cell (VSMC) proliferation and cardiac hypertrophy. However, whether stains also can inhibitin vitromyocardial hypertrophy or not still remains elusive. The purpose of this study was to explore the effects of simvastatin on the hypertrophy of cultured rat cardiomyocytes induced by CT-1 and to investigate whether this effect was mediated via JAK-STAT signaling pathway. Primary cardiomyocytes from 2-day-old (P2) rats were cultured, stimulated with CT-1, and treated with various concentration of simvastatin. Incorporation of [(3)H] leucine, reverse transcription-polymerase chain reaction and western blotting techniques were used to investigate cardiacmyocyte size, ANP mRNA and JAK-STAT protein expression. Simvastatin was proved, in a dose-independent manner, to decrease cardiacmyocytes size as well as protein synthesis, and inhibit ANP mRNA synthesis and JAK-STAT protein express...Continue Reading

References

Dec 1, 1990·The American Journal of Physiology·R A Wolf
Feb 14, 1995·Proceedings of the National Academy of Sciences of the United States of America·D PennicaK R Chien
Feb 28, 1998·Journal of Molecular and Cellular Cardiology·M A HeftiM C Schaub
Jan 12, 1999·Cellular Signalling·T YamazakiY Yazaki
Sep 18, 1999·Cell·K R Chien
Oct 21, 1999·The New England Journal of Medicine·J J Hunter, K R Chien
Nov 24, 1999·Clinical and Experimental Pharmacology & Physiology·J D LuoX Chen
Jun 9, 2000·Annual Review of Physiology·W R MacLellan, M D Schneider
Feb 22, 2001·Annual Review of Physiology·J D Molkentin, G W Dorn
Mar 7, 2001·American Heart Journal·B A VakiliR B Devereux
Mar 30, 2002·Cardiovascular Research·Ulrich LaufsGeorg Nickenig
May 11, 2002·Basic Research in Cardiology·Nikos WernerUlrich Laufs
Jan 14, 2003·Annual Review of Physiology·N Frey, E N Olson
Sep 19, 2003·European Journal of Clinical Pharmacology·Shuren LiPeter Valent

❮ Previous
Next ❯

Citations

Jun 12, 2009·Clinical and Experimental Pharmacology & Physiology·Wan-Gang GuoQiang-Sun Zheng
Jan 13, 2011·American Journal of Physiology. Endocrinology and Metabolism·Alexander P TuckowLeonard S Jefferson
Nov 16, 2017·Oxidative Medicine and Cellular Longevity·Nawal M Al-RasheedAyman M Mahmoud
Aug 19, 2007·European Journal of Clinical Investigation·F Simko
Sep 17, 2008·Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia·David Stejskal, Viktor Ruzicka
Mar 16, 2012·Endocrine·Arantxa GonzálezJavier Díez
Jul 2, 2011·Expert Reviews in Molecular Medicine·Karen E Porter, Neil A Turner
Dec 9, 2008·Journal of Molecular and Cellular Cardiology·P CalabròR Calabrò
Nov 4, 2009·European Journal of Pharmacology·Eui-Young ChoiKi-Chul Hwang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomegaly

Cardiomegaly, known as an enlarged heart, is a multifactorial disease with different pathophysiological mechanisms. Hypertension, pregnancy, exercise-induced and idiopathic causes are some mechanisms of cardiomegaly. Discover the latest research of cardiomegaly here.